Fatty Acids Derived from Royal Jelly Exert Anti-Inflammatory and Antibacterial Activities in the Treatment of Pseudomonas aeruginosa -Induced Acute Pneumonia
Journal of Medicinal Food · 2025
DOI: 10.1089/jmf.2024.k.0153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Food, 2025. Verfasst von Jiangqin Dai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Inflammatory Agents, Anti-Bacterial Agents, Pseudomonas Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Pseudomonas aeruginosa, an opportunistic pathogen, commonly causes hospital-acquired pneumonia. Royal jelly fatty acids (RJFAs), a mixture of various fatty acids extracted from royal jelly, exhibit antibacterial and anti-inflammatory properties in treating many infectious diseases. Nevertheless, the therapeutic mechanisms of RJFAs in treatment of acute P. aeruginosa pulmonary infection are still unclear. Herein, we initially extracted the fatty acids from royal jelly and characterized their chemical constituents using headspace gas chromatography-mass spectrometry. Furthermore, we examined the antibacterial effect of RJFAs in vitro and explored its therapeutic effect and molecular mechanisms in treating acute P. aeruginosa pulmonary infection in vivo. The in vitro antibacterial studies revealed that RJFAs significantly inhibited P. aeruginosa growth. Moreover, the in vivo studies showed that the RJFAs effectively mitigated the lung damage and inflammation induced by P. aeruginosa through impairing neutrophil infiltration, reducing the bacterial load in lung and diminishing the production of proinflammatory cytokines, including tumor necrosis factor (TNF-α), interleukin (IL-1β), IL-6, and macrophage inflammatory protein-2 (MIP-2). In addition, the mice treated with RJFAs exhibited reduced phosphorylation of extracellular signal-regulated kinase (ERK), p38, c-Jun N-terminal kinase (JNK), c-Jun, and nuclear factor-kappa B (NF-κB) p65 in the lung tissues in comparison with that of the mice without drug treatment. These findings demonstrated that RJFAs exhibited significant antibacterial and anti-inflammatory effects in treating the P. aeruginosa-induced acute pneumonia, and the anti-inflammatory effects were exerted through suppressing the mitogen-activated protein kinase/activator protein-1 (MAPK/AP-1) pathway and NF-κB activation, suggesting a promising therapeutic potential of RJFAs against acute bacterial pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Institute of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
Zitieren
APA
Dai, J., Guan, H., Zhang, L., Jiang, H., Su, W., Wang, J., Jia, X., & Pang, Z. (2025). Fatty Acids Derived from Royal Jelly Exert Anti-Inflammatory and Antibacterial Activities in the Treatment of Pseudomonas aeruginosa -Induced Acute Pneumonia. Journal of Medicinal Food. https://doi.org/10.1089/jmf.2024.k.0153
Vancouver
Dai J, Guan H, Zhang L, Jiang H, Su W, Wang J, et al. Fatty Acids Derived from Royal Jelly Exert Anti-Inflammatory and Antibacterial Activities in the Treatment of Pseudomonas aeruginosa -Induced Acute Pneumonia. Journal of Medicinal Food. 2025. doi:10.1089/jmf.2024.k.0153
BibTeX
@article{Dai2025,
author = {Dai, Jiangqin and Guan, Haixing and Zhang, Linlin and Jiang, Hehe and Su, Wen and Wang, Jue and Jia, Xiaolei and Pang, Zheng},
title = {Fatty Acids Derived from Royal Jelly Exert Anti-Inflammatory and Antibacterial Activities in the Treatment of Pseudomonas aeruginosa -Induced Acute Pneumonia},
journal = {Journal of Medicinal Food},
year = {2025},
doi = {10.1089/jmf.2024.k.0153}
}
EUVIMED